REMARKS

Applicants have amended the specification to further clarify the sequence ID numbers from the

Sequence Listing filed herewith. The Amendment does not introduce new matter, and is supported by

the application.

Continued examination of the present application is respectfully requested.

CONCLUSION

Applicants respectfully request consideration of this application and timely allowance of the

pending claims. Should the Examiner deem that any further action by Applicants or Applicants'

undersigned representative is desirable and/or necessary, the Examiner is invited to telephone the

undersigned at the number set forth below.

If there are any other fees due in connection with the filing of this response, please charge the

fees to deposit Account No. 50-0925. If a fee is required for an extension of time under

37 C.F.R. § 1.136 not accounted for above, such extension is requested and should also be charged to

said Deposit Account.

Respectfully submitted,

Luke A. Kilyk

Reg. No. 33,251

Atty. Docket No. 3190-015

KILYK & BOWERSOX, P.L.L.C.

53 A East Lee Street

Warrenton, VA 20186

Tel: (540) 428-1701

Fax.: (540) 428-1720

-3-

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

On page 15, paragraph beginning on line 23 and ending on line 19 of page 16.

The amplification of the mutant fragments was carried out using synthesized DNA primers containing mutation sequences and a high fidelity DNA polymerase (KOD Dash, Toyobo Co., Japan), and the amplified fragments were purified by the agarose electrophoresis, phosphorylated, self-ligated, and transformed in Escherichia coli. Substitution of the nucleotide was confirmed by DNA-sequencing. Deletion and substitution of the spiral part of stem loop III was carried out by the fusion PCR (Virology 214, 611-618 (1995)). A forward primer (GGTTAAATTTCGAGGTAAAAATTGCTATA), SEQ ID NO. 8, containing nt6029-6050 and nt6062-6080 of PSIV sequence and a reverse primer containing nt27-5 of pT7Blue (Novagen, Inc.) were synthesized for the initial amplification to delete nucleotide (nt) 6051-6061. Then, a reverse primer (CCTCGAAATTTAACCAGATCACATAGTCAGCTTTC), SEO. ID. NO. 9, containing nt6043-6029 and nt6017-5998 of PSIV sequence and a forward primer containing nt28-47 of pT7Blue (Novagen, Inc.) were synthesized for another initial amplification to delete nt6028-6018. Underlines of these primers indicate 15nt overlap of the fusion PCR. After each initial amplification using these two primer sets, two amplified DNA fragments were mixed and fused according to the description in Ref. 17. The final amplification was carried out using primers carrying nt28-47 and nt27-5 of pT7Blue, and the amplified DNA fragments were purified with a gel, phosphorylated, and ligated. The initial amplification was carried out using longer primers containing a substituted nucleotide to substitute the helical part.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Applicant(s): NAKASHIMA et al. pplication No.: 10/088,750 Group Art Unit: To Be Assigned Filed: March 20, 2002 Title: A NOVEL HIGHER-ORDER STRUCTURE WITH Examiner: To Be Assigned PROMOTING TRANSLATION ACTIVITY Attorney Docket No.: 3190-015 Commissioner for Patents Washington, D.C. 20231 DRAWING TRANSMITTAL LETTER Sir: Enclosed herewith please find: (X) 2 sheets of redlined drawing(s) which indicate proposed changes to the drawing(s). Upon approval of these proposed changes, formal drawing(s) will be submitted. sheets of corrected formal drawing(s), as required by the Notice of Patent Drawings Objection (PTO-948) which accompanied the Office Action dated sheets of corrected formal drawing(s), as required by the Notice of Patent Drawing(s) Objection (PTO-948) and approved in the Notice of Allowability dated sheets of formal drawing(s). Please substitute these formal drawing(s) for the informal drawing(s) originally filed. Examiner's approval of the entry of these drawings is respectfully requested. No new matter has been added. Respectfully Submitted, 'Express Mail" label no. <u>EV152266267 US</u> Date of Deposit: July 18, 2002

I hereby certify that this is being deposited with the United States Postal Service 'Express Mail Post Office to Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Typed Name: Dawn M. Berry

Signature: Days M. Belory

Luke A. Kilyk Reg. No. 33,251

KILYK & BOWERSOX, P.L.L.C.

53 A East Lee Street Warrenton, VA 20186

Warrenton, VA 20186 Date: July 18, 2002 Tel. (540) 428-1701

Fax: (540) 428-1720




FIG.8

